{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.0","value":"12.9"},{"groupId":"OG001","spread":"10.1","value":"11.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"OS is defined as the time from randomization to the date of death due to any cause.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were randomized to receive 6.0 mg/kg of DS-1062a.","id":"OG000","title":"DS-1062a 6.0 mg/kg"},{"description":"Participants were randomized to receive 75 mg/m\\^2 docetaxel.","id":"OG001","title":"Docetaxel 75 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set includes all randomized subjects. If a subject was randomized more than once, only one of the participants is included in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From randomization until date of death due to any cause, up to to approximately 38 months","title":"Overall Survival (OS) Following DS-1062a Versus Docetaxel","type":"PRIMARY","unitOfMeasure":"months"}